Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study (Q34484483)

2 August 2017

title

Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study (English)

1 reference

2 August 2017

0 references

anti-retroviral agent

0 references

6

Koya Ariyoshi

1 reference

2 August 2017

2

Panita Pathipvanich

1 reference

2 August 2017

Naho Tsuchiya

1

1 reference

2 August 2017

Nuanjun Wichukchinda

3

1 reference

2 August 2017

Archawin Rojanawiwat

4

1 reference

2 August 2017

Wattana Auwanit

5

1 reference

2 August 2017

Pathom Sawanpanyalert

7

1 reference

2 August 2017

publication date

30 October 2014

1 reference

2 August 2017

published in

BMC Infectious Diseases

1 reference

2 August 2017

volume

14

1 reference

2 August 2017

page(s)

565

1 reference

Creative Commons Attribution 4.0 International

2 August 2017

copyright license

start time

30 October 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Changing burden of HIV/AIDS to clinical settings in Northern Thailand over 15 years.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Individualization of antiretroviral therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in Northern Thailand

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

HLA-B*5701 screening for hypersensitivity to abacavir

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

6 July 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12879-014-0565-5

National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12879-014-0565-5

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12879-014-0565-5

HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12879-014-0565-5

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12879-014-0565-5

Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12879-014-0565-5

HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12879-014-0565-5

HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12879-014-0565-5

Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Executive summary. April 2002

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226857

HLA-Cw8 primarily associated with hypersensitivity to nevirapine

27 October 2018

1 reference

12 December 2020

Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database

1 reference

12 December 2020

Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level

1 reference

12 December 2020

Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008

1 reference

12 December 2020

10.1186/S12879-014-0565-5

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference

2 August 2017

1 reference